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IJGO at the FIGO 2012 Congress and beyondTimothy R.B. Johnson, MD
Editor, IJGOThis is an especially exciting year for the International Journal of
Gynecology and Obstetrics (IJGO). As the official journal of the Interna-
tional Federation of Gynecology and Obstetrics (FIGO), IJGO's mission
is to support the activities of the organization, its Executive Board,
and its constituent societies, and we are particularly happy to support
and be part of the 2012 FIGO Congress in Rome (October 7–12).
We have just learnt that the 2011 Impact Factor (IF) of the IJGOwas
2.045, which achieves our IF goal of above 2.0 (IF2) a year ahead of the
target we had set for ourselves. The IF is a measure of how often
publications are cited and quoted by other authors and scholars, and
this is an important benchmark for IJGO as many authors need to pub-
lish in journals with an IF2 for academic promotion and demonstra-
tion of their scholarship. IJGO has been able to achieve this goal by
maintaining its priority of publishing important documents from
FIGO, such as the FIGO Gynecologic Cancer Staging [1], the recent
FIGO Abnormal Uterine Bleeding Classification (PALM COEIN) [2],
and important opinions from, for example, the Ethics Committee
[3,4], the Safe Motherhood and Newborn Health Committee [5], and
the FIGO Working Group on the Prevention of Unsafe Abortion and
its Consequences [6]. In addition, our special contributions, such as
the section on Ethical and Legal Issues in Reproductive Health by0020-7292/$ – see front matter © 2012 International Federation of Gynecology and Obstetrics.
doi:10.1016/j.ijgo.2012.07.002Professors Dickens and Cook and special editorials by members of the
Editorial Board and the Executive Board, have been important additions.
Ourmajor goal is to publish clinically importantmaterial, but also to
support the developing scholarship and publication from low-resource
countries and those countries that are not commonly heard from. This
year includes papers from Morocco, Jordan, Guatemala, Dominican
Republic, and Bahrain—just to mention a few of the smaller countries—
but also papers from countries that do not often publish in the English
international literature, such as Russia, Georgia, Slovenia, and others.
IJGO, because of its international focus, has recently been able to
publish major randomized clinical trials that add to the evidence-
based literature on the gynecologic and obstetric use of misoprostol
[7,8], the use of tranexamic acid to prevent and manage postpartum
hemorrhage (PPH) [9], and innovative clinical approaches to the
management of PPH [10]. In addition, we have published important
papers describing clinical programs that can improve outcomes and
health through the implementation of evidence-based practices and
interventions [11,12]. I would be remiss if I did not acknowledge
with gratitude the hard work and loyal commitment of Clare
Addington, Pete Chapman, and Helen Metherell in the London office,
and Paula Flynn, the Journal Manager, in Shannon.
During this exciting year, members of the Editorial team are
delighted to be participating at the FIGO Congress in Rome. IJGO will
have a booth in the Exhibition Hall, where the Editor and Managing
Editor will be available for discussion and engagement. On Thursday
afternoon, October 11, there will be a special author workshop, with
presentations from the Editor and some of our Associate Editors
discussing the journal and how tomaximize getting published. Anyone,
especially young obstetricians/gynecologists, interested in publishing
in the IJGO should come along and hear about the Journal's priorities
and receive useful advice on writing tips, our requirements, and the
submission and review process. The Romemeetingwill be an outstand-
ing opportunity for FIGO and IJGO to highlight the contributions that
they make to women's health. IJGO is extremely pleased to be publish-
ing, once again, a World Report on Women's Health [13], edited by
President-Elect Professor Sir Sabaratnam Arulkumaran, which gives a
clear direction and vision for the activities of FIGO under the leadership
of its Chief Executive, Professor Hamid Rushwan.
We look forward to a bright and exciting future for the Journal and
hope to share our vision and engage your thoughts and suggestions at
the FIGO Congress in Rome.References
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